Heads: Veeda Clinical Research acquires European CRO - Heads

Heads gain access to the Indian and South-East Asian markets, offering access of patient population to its clientsVeeda Clinical Research has acquired Heads, a privately held European CRO, which specialises in conducting clinical trials in oncology. Established in 2010, Heads has an operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post-commercial launch.The acquisition provides Heads with a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets. India's diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases. With this acquisition, Veeda's global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, the US and the Asia Pacific. Veeda's ever-growing relationship with large biopharma companies and access to KOL's across multiple countries will accelerate the execution of global clinical trials in both the western and eastern populations. In recent years, Veeda ...